Zelira Therapeutics Ltd (ZLD) - Cash Flow Conversion Efficiency

Latest as of June 2025: 0.530x

Based on the latest financial reports, Zelira Therapeutics Ltd (ZLD) has a cash flow conversion efficiency ratio of 0.530x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-2.27 Million ≈ $-1.61 Million USD) by net assets (AU$-4.29 Million ≈ $-3.04 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Zelira Therapeutics Ltd (ZLD) market capitalisation for the company's overall valuation and market capitalisation.

Zelira Therapeutics Ltd - Cash Flow Conversion Efficiency Trend (2004–2025)

This chart illustrates how Zelira Therapeutics Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Zelira Therapeutics Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Zelira Therapeutics Ltd ranked by their cash flow conversion efficiency. Explore how high is Zelira Therapeutics Ltd's earnings quality to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Austin Metals Ltd
AU:AYT
-0.023x
Archies Limited
NSE:ARCHIES
0.015x
Ambertech Ltd
AU:AMO
-0.183x
Emico Holdings Bhd
KLSE:9091
0.017x
MT Malcolm Mines NL
AU:M2M
-0.056x
Rank Group PLC
LSE:RNK
0.163x
Belmont Resources Inc
V:BEA
-0.038x
RenX Enterprises Corp.
NASDAQ:RENX
-0.438x

Annual Cash Flow Conversion Efficiency for Zelira Therapeutics Ltd (2004–2025)

The table below shows the annual cash flow conversion efficiency of Zelira Therapeutics Ltd from 2004 to 2025. View current stock price of Zelira Therapeutics Ltd for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$-4.29 Million
≈ $-3.04 Million
AU$-4.91 Million
≈ $-3.47 Million
1.144x +8.76%
2024-06-30 AU$-4.17 Million
≈ $-2.95 Million
AU$-4.39 Million
≈ $-3.11 Million
1.052x +560.04%
2023-06-30 AU$31.71 Million
≈ $22.44 Million
AU$-7.25 Million
≈ $-5.13 Million
-0.229x +13.46%
2022-06-30 AU$35.69 Million
≈ $25.25 Million
AU$-9.43 Million
≈ $-6.67 Million
-0.264x -15.97%
2021-06-30 AU$37.83 Million
≈ $26.77 Million
AU$-8.62 Million
≈ $-6.10 Million
-0.228x -13.45%
2020-06-30 AU$34.55 Million
≈ $24.44 Million
AU$-6.94 Million
≈ $-4.91 Million
-0.201x +81.34%
2019-06-30 AU$3.11 Million
≈ $2.20 Million
AU$-3.34 Million
≈ $-2.37 Million
-1.076x -154.74%
2018-06-30 AU$6.21 Million
≈ $4.40 Million
AU$-2.62 Million
≈ $-1.86 Million
-0.422x -51.54%
2017-06-30 AU$7.90 Million
≈ $5.59 Million
AU$-2.20 Million
≈ $-1.56 Million
-0.279x -117.04%
2016-06-30 AU$-202.91K
≈ $-143.57K
AU$-331.82K
≈ $-234.78K
1.635x +299.81%
2015-06-30 AU$357.87K
≈ $253.22K
AU$-292.89K
≈ $-207.24K
-0.818x -122.24%
2014-06-30 AU$750.16K
≈ $530.78K
AU$-276.25K
≈ $-195.47K
-0.368x -47.42%
2013-06-30 AU$1.04 Million
≈ $736.13K
AU$-259.89K
≈ $-183.89K
-0.250x +41.03%
2012-06-30 AU$1.35 Million
≈ $956.78K
AU$-572.82K
≈ $-405.31K
-0.424x -374.87%
2011-06-30 AU$661.35K
≈ $467.95K
AU$101.92K
≈ $72.12K
0.154x +108.53%
2010-06-30 AU$654.33K
≈ $462.98K
AU$-1.18 Million
≈ $-836.78K
-1.807x -185.06%
2009-06-30 AU$2.48 Million
≈ $1.75 Million
AU$-1.57 Million
≈ $-1.11 Million
-0.634x +63.41%
2008-06-30 AU$1.28 Million
≈ $902.96K
AU$-2.21 Million
≈ $-1.56 Million
-1.733x -273.67%
2007-06-30 AU$-14.84 Million
≈ $-10.50 Million
AU$-14.81 Million
≈ $-10.48 Million
0.998x +309.39%
2006-06-30 AU$14.88 Million
≈ $10.53 Million
AU$-7.09 Million
≈ $-5.02 Million
-0.476x -83.61%
2005-06-30 AU$9.88 Million
≈ $6.99 Million
AU$-2.56 Million
≈ $-1.81 Million
-0.260x +21.82%
2004-06-30 AU$8.29 Million
≈ $5.87 Million
AU$-2.75 Million
≈ $-1.95 Million
-0.332x --

About Zelira Therapeutics Ltd

AU:ZLD Australia Biotechnology
Market Cap
$4.65 Million
AU$6.57 Million AUD
Market Cap Rank
#28828 Global
#1561 in Australia
Share Price
AU$0.50
Change (1 day)
+0.00%
52-Week Range
AU$0.31 - AU$0.91
All Time High
AU$26.25
About

Zelira Therapeutics Limited, a biopharmaceutical company, engages in the research, development, and commercialization of cannabinoid-based medicines for the treatment of various medical conditions in Australia and the United States. It offers formulations under the HOPE brand in Australia, Washington, Pennsylvania, and Louisiana, as well as develops ZENIVOL, a cannabinoid drug for the treatment o… Read more